There's been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor. There are currently two products on the market from Novartis and a slew of clinical trials underway. Interest is so high that within the past year it has been at the center of a flurry of acquisition announcements by big pharma.
mountain Perspective Therapeutics year to date Cantor Fitzgerald is also bullish on the name. "Even though the stock has had a good run this year … we still see room for shares to go higher. Our analysis arrives at an equity value over $4B, compared to its current market cap of ~$1B," analyst Louise Chen wrote in a note last week. The company has been a bit under big pharma's radar since it did a reverse merger to go public just last year, Jones pointed out.
mountain Lantheus Holdings year to date The company also struck multiple strategic agreements with Perspective Therapeutics in January, including an option to exclusively license Perspective's clinical stage alpha therapy developed for the treatment of neuroendocrine tumors and an option to co-develop certain early stage therapeutic candidates targeting prostate cancer. In addition, Lantheus agreed to purchase up to 19.
المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: Investingcom - 🏆 450. / 53 اقرأ أكثر »